Navigation Links
Schering-Plough CEO Buys $2 Million in Common Shares
Date:4/24/2008

KENILWORTH, N.J., April 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that Chairman and CEO Fred Hassan purchased just over $2 million of Schering-Plough common stock, or 110, 000 shares at an average purchase price of $18.26 per share.

"As I said when I announced my intention to purchase these shares in January, this investment in Schering-Plough reflects my long-term confidence in the company, its products -- including ZETIA and VYTORIN -- and our late- stage pipeline," said Hassan.

Hassan has said on January 18 that he intended to purchase the shares as soon as the transaction received legal clearance. That clearance was issued this morning, based upon first quarter earnings having been reported yesterday.

Full details of the purchase will be reported on a Form 4 filed with the SEC and available on Schering-Plough's Web site today or tomorrow.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
2. Schering-Plough Reports Financial Results for First Quarter of 2008
3. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
4. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
5. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
7. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
8. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
9. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
10. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
11. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Calif., July 22 CV Therapeutics,Inc. (Nasdaq: CVTX ... results for 2008 after the market closes on Thursday, ... at 5:00 p.m. EDT,2:00 p.m. PDT, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... is bringing aboard Ashton S. Maaraba, a key Pharmacy, Pharmacy Services ... , ... (PRWEB) July 22, 2008 -- PharmaSmart International ... Ashton S. Maaraba, a key Pharmacy, Pharmacy Services & HBC industry ...
... U.S. Department of Energy,s Lawrence Berkeley National Laboratory (Berkeley ... performed the first scanning tunneling spectroscopy of graphene flakes ... latest in a series of surprising insights into the ... carbon: an unexpected gap-like feature in the energy spectrum ...
Cached Biology Technology:CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2A phonon floodgate in monolayer carbon 2A phonon floodgate in monolayer carbon 3A phonon floodgate in monolayer carbon 4A phonon floodgate in monolayer carbon 5
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
(Date:7/9/2014)... receptor antagonists can alleviate the symptoms of ... cognitive dysfunction and effectively scavenge amyloid beta ... (Aβ) vaccines reduced and eliminated Aβ deposition ... model, and significantly improved behavioral and cognitive ... First Affiliated Hospital of China Medical University, ...
(Date:7/9/2014)... inhabitants of the sea: tiny haptophytes of the type ... eye, when they are in bloom in spring, they ... on satellite images. "Together with other phytoplankton, Emiliania ... global photosynthesis output," states Prof. Dr. Georg Pohnert of ... the greenhouse gas carbon dioxide CO2 is ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Short circuit in the food web 2
... tropical parasitic disease that can lead to life-threatening heart ... than previously thought, according to research from The University ... for four years now, and this year the number ... professor of integrative biology and philosophy at The University ...
... Cincinnati, OH, October 6, 2011 -- Directly advertising food ... providers, and the American Academy of Pediatrics and the ... impact of advertising on children,s healthy food choices. ... Journal of Pediatrics explores the relationship between ...
... can ever know about long-gone creatures is what they ... resurrect actual specimens and compare their features with their ... Toronto biologists helping to create a seed bank that ... allowing them to measure evolution caused by global change. ...
Cached Biology News:Chagas disease may be a threat in South Texas, says researcher 2Study suggests children's food choices are affected by direct advertising and parental influence 2Seed time-capsule will aid study of plant evolution amid environmental change 2